Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug tame PCOS symptoms?

NCT ID NCT05972928

Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers are testing whether sitagliptin, a drug used for diabetes, can improve hormonal, metabolic, and weight-related issues in women with polycystic ovary syndrome (PCOS). The trial will give 80 women with PCOS a 100 mg dose of sitagliptin daily for three months. The main goal is to see if the drug helps with weight loss and other PCOS-related problems, which could also help with fertility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sitagliptin, a diabetes drug taken as a 100 mg tablet once daily for 3 months
What this could lead to
If it works, sitagliptin could offer a new way to manage PCOS symptoms and improve fertility.
What could go wrong
This is a small, early-stage trial, and sitagliptin may not improve PCOS outcomes. Possible side effects include digestive issues and low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

80 people

The number who actually took part.

Started

Aug 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present: 1. oligo- and/or anovulation 2. hyperandrogenism (HA) (clinical and/or biochemical) 3. polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3). Exclusion Criteria: 1. congenital adrenal hyperplasia 2. Brittle control of a thyroid disorder 3. Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance 4. chronic kidney disease 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycystic ovary syndrome

Contacts and locations

Locations

  • Beni-suef university Hospital

    Banī Suwayf, Beni Suweif Governorate, 62521, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.